Intensity Therapeutics(INTS)
Search documents
Intensity Therapeutics(INTS) - 2023 Q4 - Annual Results
2024-03-14 20:12
Exhibit 99.1 Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Shelton, CT, March 14, 2024 – Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces full year 2023 financial results and provides a review of 2023 a ...
Intensity Therapeutics(INTS) - 2023 Q4 - Annual Report
2024-03-14 20:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41109 INTENSITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charte ...
Intensity Therapeutics(INTS) - 2023 Q3 - Quarterly Report
2023-11-13 17:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41109 Intensity Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | ...
Intensity Therapeutics(INTS) - 2023 Q2 - Quarterly Report
2023-08-14 16:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41109 Intensity Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 46-14 ...